Evidence map›Paper›PMID 39109486›Full record

ArticleNanomedicine (London, England)2024

Nanoparticles crossing blood-brain barrier need specific design for normal, neurodegenerative or cancerous brain conditions.

Julia Y Ljubimova, Eggehard Holler, Keith L Black, Alexander V Ljubimov

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Julia Y LjubimovaTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.ORCID 0000-0002-8623-3598
Eggehard HollerTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.ORCID 0000-0001-8582-2190
Keith L BlackDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-0546-4934
Alexander V LjubimovDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0003-2398-5319

Funding

Nanoconjugate delivery of proliferation and checkpoint inhibitors to treat glial tumorsR01CA206220 · NCI · CEDARS-SINAI MEDICAL CENTER · PI LJUBIMOVA, JULIA Y · 2016 to 2020
$2.8M
Glial tumor image-guided surgery and treatmentR01CA209921 · NCI · TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION · PI HOLLER, EGGEHARD · 2016 to 2021
$2.6M
Differential MRI imaging for brain tumor metastases diagnosis and treatment monitoringR01CA188743 · NCI · CEDARS-SINAI MEDICAL CENTER · PI LJUBIMOVA, JULIA Y · 2015 to 2019
$2.5M
Targeting tumor microenvironment by nanoimmunodrugs for glioma treatmentR01CA284247 · NCI · CEDARS-SINAI MEDICAL CENTER · PI Alexander V Ljubimov · 2023 to 2026
$2.2M
NCI NIH HHS R01 CA188743NCI NIH HHS R01 CA206220NCI NIH HHS R01 CA209921NCI NIH HHS R01 CA284247
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Blood-Brain BarrierBrain NeoplasmsNanoparticlesAnimalsBrainHumansNeurodegenerative DiseasesAlzheimer's and tumorBBBblood brain barrier (BBB)cell-specific drug deliverycentral nervous systemCNS immunityDiabetic retinopathymultifunctional nanoparticlesnormalpeptides

Identifiers

PMID39109486
PMCPMC11457639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.